Drugs / HRYZ-T102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06515314 | Oct 2024 → Aug 2026 overdue | hepatocellular carcinoma | Shanghai Ruiliyuan Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRYZ-T102 | “HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors” NCT06515314 ↗ |
| Known as | HRYZ-T102 TCR-T Cell | “HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors” NCT06515314 ↗ |
| Modality | Cell therapy | “TCR-T cells” NCT06515314 ↗ |
| Route | Intravenous | “the TCR-T cells will be administered intravenously.” NCT06515314 ↗ |